Mylan Pharmaceuticals Inc. v. United States Food & Drug Administration
789 F. Supp. 2d 1
D.D.C.2011Background
- FDA is reviewing Ranbaxy's ANDA for atorvastatin while Matrix/Mylan seek injunction and disclosure of status; the case centers on standing and ripeness limits on federal jurisdiction.
- Matrix's ANDA for generic Lipitor is pending; June 28, 2011 pediatric exclusivity expiration could allow entry if Ranbaxy's exclusivity doesn’t block it.
- Ranbaxy, first to file with a paragraph IV certification, faces uncertain exclusivity status and alleged AIP-related data concerns.
- Plaintiffs allege delay in exclusivity determination harms their ability to plan launch and market access, and argue FDA should enforce the AIP if Ranbaxy's data are tainted.
- Court ultimately dismisses for lack of standing and ripeness, declining to exercise jurisdiction over challenges to a competitor's exclusivity entitlement.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether plaintiffs have standing to challenge FDA delay on Ranbaxy's exclusivity | Matrix/Mylan contend they have a concrete interest in exclusivity rights | FDA argues no imminent injury since Matrix's own ANDA is not tentatively approved | Lack of standing; no imminent, concrete injury shown |
| Whether the claims are ripe given contingent future events | Claims are ripe because Matrix's path to exclusivity is clear and imminent | Ripeness requires final agency action or concrete factual disputes; uncertainty remains | Lack of ripeness; claims not ripe for review |
Key Cases Cited
- Pfizer Inc. v. Shalala, 182 F.3d 975 (D.C. Cir. 1999) (standing to challenge FDA action in exclusivity context)
- Lujan v. Defenders of Wildlife, 504 U.S. 555 (Sup. Ct. 1992) (injury, causation, redressability requirements for standing)
- Hi-Tech Pharmacal Co., Inc. v. FDA, 587 F. Supp. 2d 1 (D.D.C. 2008) (final agency action prerequisite for certain APA challenges)
- Teva Pharms. USA, Inc. v. FDA, 595 F.3d 1311 (D.C. Cir. 2010) (standing to exclusivity before final approval under narrow facts)
- Wyoming Outdoor Council v. U.S. Forest Service, 165 F.3d 43 (D.C. Cir. 1999) (prudential standing considerations for third-party claims)